Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gregory D Curfman

Showing results (41-50 of 67) with videos related to

Pageof 7
Sort By:
The New England Journal of Medicine|July 4, 2008
Why doctors should worry about preemptionGregory D Curfman, Stephen Morrissey, Jeffrey M Drazen
The New England Journal of Medicine|July 20, 2007
Safer drugs for the American peopleGregory D Curfman, Stephen Morrissey, Jeffrey M Drazen
The New England Journal of Medicine|August 22, 2008
Health of the nation--coverage for all AmericansStephen Morrissey, Gregory D Curfman, Jeffrey M Drazen
The New England Journal of Medicine|March 2, 2012
Supreme Court review of the health care reform lawGregory D Curfman, Brendan S Abel, Renée M Landers
The New England Journal of Medicine|July 3, 2014
When religious freedom clashes with access to careI Glenn Cohen, Holly Fernandez Lynch, Gregory D Curfman
The New England Journal of Medicine|November 14, 2003
Removal of expression of concern: Schiffl H, et Al. Daily hemodialysis and the outcome of acute renal failure. N Engl J Med 2002;346:305-10Jeffrey M Drazen, Julie R Ingelfinger, Gregory D Curfman
The New England Journal of Medicine|September 4, 2014
Paradigm shifts in heart-failure therapy--a timelineChana A Sacks, John A Jarcho, Gregory D Curfman
The New England Journal of Medicine|May 23, 2003
Expression of concern: Schiffl H, et Al. Daily hemodialysis and the outcome of acute renal failure. N Engl J Med 2002;346:305-10Jeffrey M Drazen, Julie R Ingelfinger, Gregory D Curfman
The New England Journal of Medicine|May 16, 2014
The new cholesterol treatment guidelinesJohn F Keaney, Gregory D Curfman, John A Jarcho
JAMA|May 26, 2018
Antitrust, Market Exclusivity, and Transparency in the Pharmaceutical IndustryMichael S Sinha, Gregory D Curfman, Michael A Carrier
Pageof 7

Showing results (41-50 of 67) with videos related to

Sort By:
Pageof 7
The New England Journal of Medicine|July 4, 2008
Why doctors should worry about preemptionGregory D Curfman, Stephen Morrissey, Jeffrey M Drazen
The New England Journal of Medicine|July 20, 2007
Safer drugs for the American peopleGregory D Curfman, Stephen Morrissey, Jeffrey M Drazen
The New England Journal of Medicine|August 22, 2008
Health of the nation--coverage for all AmericansStephen Morrissey, Gregory D Curfman, Jeffrey M Drazen
The New England Journal of Medicine|March 2, 2012
Supreme Court review of the health care reform lawGregory D Curfman, Brendan S Abel, Renée M Landers
The New England Journal of Medicine|July 3, 2014
When religious freedom clashes with access to careI Glenn Cohen, Holly Fernandez Lynch, Gregory D Curfman
The New England Journal of Medicine|November 14, 2003
Removal of expression of concern: Schiffl H, et Al. Daily hemodialysis and the outcome of acute renal failure. N Engl J Med 2002;346:305-10Jeffrey M Drazen, Julie R Ingelfinger, Gregory D Curfman
The New England Journal of Medicine|September 4, 2014
Paradigm shifts in heart-failure therapy--a timelineChana A Sacks, John A Jarcho, Gregory D Curfman
The New England Journal of Medicine|May 23, 2003
Expression of concern: Schiffl H, et Al. Daily hemodialysis and the outcome of acute renal failure. N Engl J Med 2002;346:305-10Jeffrey M Drazen, Julie R Ingelfinger, Gregory D Curfman
The New England Journal of Medicine|May 16, 2014
The new cholesterol treatment guidelinesJohn F Keaney, Gregory D Curfman, John A Jarcho
JAMA|May 26, 2018
Antitrust, Market Exclusivity, and Transparency in the Pharmaceutical IndustryMichael S Sinha, Gregory D Curfman, Michael A Carrier
Pageof 7